Clinical Takeaway
Children born to mothers who used cannabis during pregnancy showed a small but measurable increase in risk for autism spectrum disorder and ADHD in a meta-analysis of 13 studies. Cannabis compounds cross the placental barrier and may affect developing brain cannabinoid receptors, though the observed risk increases were modest. Current evidence supports counseling pregnant patients to avoid cannabis use given these potential neurodevelopmental concerns.
#14 Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.
Citation: Andrade Chittaranjan. Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.. The Journal of clinical psychiatry. 2024. PMID: 39724097.
Design: 6 Journal: 0 N: 2 Recency: 1 Pop: 3 Human: 1 Risk: -2
This study addresses a critical gap in pediatric neurodevelopmental risk assessment given that cannabis use in pregnancy affects up to 10% of pregnant women, yet the clinical significance of gestational exposure on offspring neurodevelopment remains insufficiently characterized in routine prenatal counseling. The meta-analytic finding of a 30% increased risk of autism spectrum disorder and elevated attention-deficit/hyperactivity disorder risk provides quantified evidence that supports informed consent discussions and establishes maternal cannabis use as a documented teratogenic exposure warranting clinical consideration alongside established neurotoxicants. These findings have direct implications for obstetric counseling protocols and pediatric screening practices, particularly given the expanding legalization of cannabis and shifting perceptions of its
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Retrospective design — selection and information bias risk
Abstract: Up to 10% of women may use cannabis during pregnancy; this is of concern because constituents of cannabis cross the placental barrier and potentially influence neurodevelopment by acting on cannabinoid receptors in the developing fetal brain. In this context, a recent meta analysis of 13 observational studies found that gestational exposure to cannabis was associated with a small increase in the risk of autism spectrum disorder (ASD; relative risk [RR], 1.30) and with an even smaller increase in the risk of attention deficit/hyperactivity disorder (ADHD; RR, 1.13); the latter finding was probably supported by publication bias. In this meta-analysis, 4 studies provided information on ASD (pooled N = 178,565) and 10 on ADHD (pooled N = 203,783). In a large (n = 222,534) retrospectively ascertained cohort study published after the meta-analysis, cannabis use disorder (CUD) recorded before pregnancy, during pregnancy, and during pregnancy plus the year after delivery were associated with closely similar increased risks of ASD (RRs, 3.02-3.21). The risks were smaller in smokers (RRs, 1.74-1.87) than in nonsmokers (RRs, 4.55-4.83) but differed little between male (RRs, 3.01-3.06) and female (RRs, 2.71-2.85) offspring. Although the cohort study had many strengths, its limitations permitted only the conclusion that peri-pregnancy exposure to CUD is associated with a large increase in the risk of ASD in offspring; it remained possible that much of the risk was driven by genetic, environmental, or behavioral variables. The field is nascent; the total number of cannabis exposed pregnancies (with ASD and ADHD as the outcomes) in world literature is small. However, cannabis use during pregnancy is, at the very least, a clear marker for adverse neurodevelopmental outcomes, besides the adverse maternal, fetal, and neonatal outcomes identified in other studies. Healthcare providers who manage women who use cannabis during pregnancy need to be aware of these adverse outcomes.
🧠 While this meta-analysis suggests a modest association between prenatal cannabis exposure and increased risk of autism spectrum disorder and attention-deficit/hyperactivity disorder, it is important to recognize that observational studies are inherently limited by confounding variables including maternal psychiatric conditions, concurrent substance use, socioeconomic factors, and unmeasured lifestyle exposures that may drive both cannabis use and neurodevelopmental outcomes. The relative risks reported are small in magnitude, and the quality of evidence varies considerably across the 13 included studies, with potential bias from differential reporting and recall. Additionally, the mechanism by which cannabinoids might influence fetal neurodevelopment remains incompletely understood, and we lack data on dose, timing, frequency, and cannabinoid composition in most studies. In clinical practice, these findings support counseling pregnant patients and those planning pregnancy that cannabis use carries potential risks to fetal development, but the evidence does not yet permit definitive causal conclusions; providers should address cannabis use as part of comprehensive prenatal risk assessment while acknowledging the